Paper Review Records
All Paper Review Records
10 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
The role of the 21-gene assay in the neoadjuvant setting for hormone receptor-positive HER2-negative breast cancer: Impact on systemic and surgical treatment decisions
Á.Guerrero Zotano; T.M. Allweis; R. Foerster; C. Palmieri; O. Gluz; S. Chia; C. Sotiriou; G. BianchiniShow moreShow less
Medical Oncology Department, Instituto Valenciano de Oncología, Valencia, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Dept. of Breast Surgery, Hadassah Medical Center, Jerusalem, Israel; Faculty of Medicine, Hebrew University, Jerusalem, Israel; Exact Sciences (Abbott Cancer Diagnostics), Baar, Zug, Switzerland; The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, UK; University of Liverpool, Liverpool, UK; West German Study Group (WSG), Moenchengladbach, Germany; Breast Center Niederrhein, Ev. Hospital Bethesda, Moenchengladbach, Germany; University Clinics Cologne, Women’s Clinic and Breast Center, Cologne, Germany; Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada; Breast Cancer Translational Research Laboratory, Department of Medical Oncology, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Brussels, Belgium; Université Libre de Bruxelles (ULB), Brussels, Belgium; Medical Oncology Department, IRCCS San Raffaele Hospital, Milan, Italy; Vita-Salute San Raffaele University, Milan, ItalyShow moreShow less
Prognostic role of postoperative circulating tumor DNA in metastatic colorectal cancer treated with curative intent: A systematic review and meta-analysis
Claudia Cardone; Sergio Facchini; Bruna de Oliveira Ascef; Antonino Cassata; Alfonso De Stefano; Paolo Chiodini; Antonio AvalloneShow moreShow less
Experimental Clinical Abdominal Oncology Unit, Istituto Nazionale Tumori- IRCCS-Fondazione G. Pascale, Naples, Italy; Department of Mental and Physical Health and Preventive Medicine. Medical Statistics Unit. Università degli Studi della Campania Luigi Vanvitelli, Naples, ItalyShow moreShow less
Central nervous system and leptomeningeal metastases in patients with HER2-positive breast cancer: A comprehensive review and therapeutic algorithm proposal
Aldo Caltavituro; Roberto Buonaiuto; Alessandra Longobardi; Paola Trasacco; Claudia Martinelli; Giuseppe Di Grazia; Roberto Pacelli; Grazia Arpino; Carmine De Angelis; Roberta Caputo; Michelino De Laurentiis; Elena Laakmann; Leonor Vasconcelos de Matos; Mário Fontes-Sousa; Mette van Ramshorst; Volkmar Mueller; Elisa Agostinetto; Sabine Linn; Michelangelo De Angelis; Francesco Schettini; Mario GiulianoShow moreShow less
Oncology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; Clinical and Translational Oncology, Scuola Superiore Meridionale, Naples, Italy; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Department of Breast and Thoracic Oncology, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, Napoli, Italy; Department of Advanced Biomedical Sciences, University Federico II, Naples, Italy; University Medical Center Hamburg-Eppendorf, Department of Gynecology, Hamburg, Germany; Breast Cancer Unit, Champalimaud Clinical Centre, Champalimaud Foundation, Lisbon, Portugal; Oncology Unit, Hospital CUF Tejo, Lisbon, Portugal, Oncology Unit, Unidade Local de Saúde Lisboa Ocidental, Lisbon, Portugal; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Gynecology, University Medical Center Hamburg 20246 Hamburg, Germany; Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Bruxelles, Belgium; Department of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands; IRCCS Istituto Neurologico Mediterraneo Neuromed, Division of Neurosurgery, Isernia, Italy; Clinic Barcelona Comprehensive Cancer Center, Hospital Clinic of Barcelona, Barcelona, Spain; Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, SpainShow moreShow less
KRAS G12C-mutant non-small cell lung cancer: A practical guide for clinicians
Jordi Remon; Giulia La-Cava; Maxime Borgeaud; Stephanie P.L. Saw; Lizza EL Hendriks; Biagio RicciutiShow moreShow less
Department of Medical Oncology, Thoracic Group, Gustave Roussy, Villejuif, France; Paris-Saclay University, Paris, France; Department of Medicine and Surgery, University Campus Bio-Medico of Rome, Rome, Italy; Oncology Department, University Hospital Geneva, Geneva, Switzerland; Division of Medical Oncology, National Cancer Centre Singapore, Singapore; Department of Pulmonary Diseases, Maastricht University Medical Centre (+), GROW Research Institute for Oncology and Reproduction, Maastricht, the Netherlands; Lowe Center of Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United StatesShow moreShow less
Circulating tumor DNA for predicting recurrence and mortality in patients with resected Melanoma: A systematic review and meta-analysis
Pedro C. Abrahão Reis; Mariana Macambira Noronha; João Pedro Oliveira; João Evangelista Ponte Conrado; Isabella Romagnoli Buonopane; Carlos Diego Holanda Lopes; Daniel V. Araujo; Erick F. SaldanhaShow moreShow less
Universidade Federal do Rio de Janeiro (UFRJ), RJ, Brazil; Universidade Federal do Ceará (UFC), CE, Brazil; Universidade Federal da Bahia (UFBA), BA, Brazil; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, ON, Canada; Department of Medicine, University of Toronto, ON, Canada; University of Florida, Gainesville, FL, USA; Harvard T. H. Chan School of Public Health, Harvard University, MA, USAShow moreShow less
Targeting key epigenetic regulators in solid tumors: focus on EZH2, PRMT5, and BET inhibitors
Irene Hernández de Córdoba Sánchez; Mercedes Avedillo Ruidiaz; Victor Moreno; Henry Long; Paloma CejasShow moreShow less
Department of Medical Oncology, University Hospital Infanta Sofía, San Sebastián de los Reyes, 28702 Madrid, Spain; Department of Medical Oncology, University Hospital Fundación Jiménez Díaz, Moncloa-Aravaca, 28040 Madrid, Spain; START Madrid-FJD Early Phase Clinical Trials Unit, University Hospital Fundación Jiménez Díaz, 28040 Madrid, Spain; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USAShow moreShow less
FAQ
How long does CANCER TREATMENT REVIEWS take to review a manuscript?
As of 2026-11-19, CrushSCI has 10 complete review records for CANCER TREATMENT REVIEWS. The fastest paper went from submission to acceptance in 27 days (The role of the 21-gene assay in the neoadjuvant setting for hormone receptor-positive HER2-negative breast cancer: Impact on systemic and surgical treatment decisions, received 2026-04-28, accepted 2026-05-25); the slowest took 66 days. The average is 47.6 days and the median is 48.5 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
